全文获取类型
收费全文 | 36359篇 |
免费 | 2243篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 323篇 |
儿科学 | 1171篇 |
妇产科学 | 1014篇 |
基础医学 | 4979篇 |
口腔科学 | 617篇 |
临床医学 | 5941篇 |
内科学 | 6590篇 |
皮肤病学 | 598篇 |
神经病学 | 3470篇 |
特种医学 | 610篇 |
外科学 | 3149篇 |
综合类 | 408篇 |
一般理论 | 55篇 |
预防医学 | 4558篇 |
眼科学 | 469篇 |
药学 | 2142篇 |
中国医学 | 68篇 |
肿瘤学 | 2550篇 |
出版年
2023年 | 197篇 |
2022年 | 382篇 |
2021年 | 775篇 |
2020年 | 459篇 |
2019年 | 781篇 |
2018年 | 897篇 |
2017年 | 620篇 |
2016年 | 648篇 |
2015年 | 833篇 |
2014年 | 1173篇 |
2013年 | 1781篇 |
2012年 | 2654篇 |
2011年 | 2807篇 |
2010年 | 1531篇 |
2009年 | 1287篇 |
2008年 | 2545篇 |
2007年 | 2548篇 |
2006年 | 2571篇 |
2005年 | 2393篇 |
2004年 | 2312篇 |
2003年 | 2196篇 |
2002年 | 2049篇 |
2001年 | 224篇 |
2000年 | 160篇 |
1999年 | 301篇 |
1998年 | 412篇 |
1997年 | 367篇 |
1996年 | 328篇 |
1995年 | 280篇 |
1994年 | 272篇 |
1993年 | 254篇 |
1992年 | 171篇 |
1991年 | 141篇 |
1990年 | 135篇 |
1989年 | 132篇 |
1988年 | 114篇 |
1987年 | 113篇 |
1986年 | 100篇 |
1985年 | 108篇 |
1984年 | 159篇 |
1983年 | 160篇 |
1982年 | 195篇 |
1981年 | 168篇 |
1980年 | 159篇 |
1979年 | 96篇 |
1978年 | 79篇 |
1977年 | 83篇 |
1976年 | 63篇 |
1974年 | 72篇 |
1973年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
3.
Patricia A Wilkosz Sachiko Miyahara Oscar L Lopez Steven T Dekosky Robert A Sweet 《The American journal of geriatric psychiatry》2006,14(4):352-360
BACKGROUND: Psychotic symptoms in Alzheimer disease (AD+P) identify a heritable phenotype associated with more rapid cognitive decline. The authors have proposed that AD+P is itself a composite of a misidentification and a paranoid subtype with increased cognitive impairment restricted to the misidentification type. Most prior studies of the clinical correlates of AD+P have been limited, however, by the inclusion of prevalent cases. METHODS: Subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis at study entry were assessed at the time of initial presentation and then annually. Psychotic symptoms were assessed using the CERAD Behavioral Rating Scale. Survival analyses used Cox proportional hazard models with time-dependent covariates to examine the predictors of psychosis onset. RESULTS: A total of 288 subjects completed at least one follow-up examination. Mean duration of follow-up was 22.1 months. The incidence of psychosis was 0.19 per person-year. Cognitive impairment was associated with onset of psychosis, largely as a result of its association with onset of the misidentification, but not the paranoid, subtype. Including psychotropic medication use in the model revealed an association of antidepressant use with the onset of psychosis. This latter association appeared to arise from an underlying association between depression and the risk of psychosis onset rather than from antidepressant treatment. CONCLUSION: These findings are consistent with the hypothesis that the misidentification and the paranoid subtypes each define a more biologically homogeneous group than AD+P as a whole. Further exploration of the relationship between depressive symptoms and psychosis in patients with AD is warranted. 相似文献
4.
Paul C. Willems Leon Elmans Patricia G. Anderson Wilco C. H. Jacobs Dick B. van der Schaaf Marinus de Kleuver 《European spine journal》2006,15(10):1487-1494
The results of lumbar fusion in chronic low back pain (LBP) patients vary considerably, and there is a need for proper patient selection. Lumbosacral orthoses have been widely used to predict outcome, however, with little scientific support. The aim of the present study was to determine the value of a pantaloon cast test in selecting chronic LBP patients for lumbar fusion or conservative management. First, a systematic review of the literature was carried out in which two independent reviewers identified studies in Medline, Cochrane and Current Contents databases. Three papers met the selection criteria. In the only study with a control group, a significantly better outcome after fusion compared to conservative treatment was found in patients who reported significant pain relief while in a cast (i.e. a positive cast test). The results of lumbar fusion, however, were not significantly different for patients with a positive and those with a negative cast test. In addition to the review, a clinical cohort study of 257 LBP patients, who had been allocated to either lumbar fusion or conservative management by a temporary external transpedicular fixation trial, was performed. Prior to allocation, all had undergone a pantaloon cast test. Patients with no history of prior spine surgery and with a positive pantaloon cast test had a better outcome after lumbar fusion than those treated conservatively (P = 0.002, χ
2 test). In patients with previous spine operations the outcomes were poor and the test was of no value. From the literature and the present patient cohort, it was concluded that only in chronic LBP patients without prior spine surgery, a pantaloon cast test with substantial pain relief suggests a favorable outcome of lumbar fusion compared to conservative management. The test has no value in patients who have had previous spine surgery. 相似文献
5.
The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing 总被引:1,自引:0,他引:1
Kevin Conway MRCS ; Patricia Price PhD ; Keith G. Harding FRCS ; Wen G. Jiang MD 《Wound repair and regeneration》2006,14(1):2-10
Wound healing involves a number of cellular and molecular events, many of which are controlled by soluble growth factors. In the process of healing, hepatocyte growth factor, a cytokine known to act as mitogen, motogen, and morphogen, has been postulated to play multiple roles during several stages of this complex biological process. Produced primarily by stromal fibroblasts, hepatocyte growth factor regulates angiogenesis, vascular permeability, cell migration, matrix deposition and degradation, and other biological processes. The current article discusses recent progress in understanding the multiple roles played by this growth factor in tissue repair. 相似文献
6.
Daniel D. Billadeau Subrha Chatterjee Patricia Bramati Raghavakaimal Sreekumar Vijay Shah Karen Hedin Raul Urrutia 《Journal of gastrointestinal cancer》2006,37(4):110-119
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1α, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease. 相似文献
7.
8.
9.
Cheryl Wallerstedt RNC MS Patricia Higgins RN PhD 《Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG》1996,25(5):389-400
Society often expects mothers and fathers to share equally in the perinatal grief process because the child was a common bond between them. Unfortunately, in perinatal grief, this is not always the case. The mother and the father can experience incongruent grieving and use discordant coping mechanisms. It is important to evaluate these differences to facilitate communication between the distraught parents. Improved communication can in turn facilitate the grieving process. 相似文献
10.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献